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Abstract
Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of
many human diseases, including cancer and neurodegenerative disorders. The recent approval of
the proteasome inhibitor Velcade® (bortezomib) for the treatment of multiple myeloma and mantle
cell lymphoma establishes this system as a valid target for cancer treatment. We review here new
patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS
components, such as E3 ubiquitin ligases and deubiquitylating enzymes.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Introduction
The ubiquitin proteasome system is an important non-lys-
osomal protein degradation pathway. Ubiquitin is a 76
amino acid polypeptide highly conserved throughout
evolution and abundant in eukaryotic cells [1-3]. The con-
jugation of ubiquitin to protein substrates is a multi-step
process involving ubiquitin activation by the E1 conjugat-
ing enzyme and its transfer, mediated by ubiquitin conju-
gases (E2) and E3 ubiquitin ligases, to an internal lysine
residue on the substrate [4-7].
The covalent attachment of multi-ubiquitin molecules
(linked by lysines at residues 48) to target substrates
mostly leads to protein degradation by the multi-catalytic
proteasome complex [8-10]. Mono- and polyubiquityla-
tion can be reversed by deubiquitylating enzymes
(DUBs), which specifically cleave the isopeptide bond at
the C-terminus of ubiquitin [11]. Changes in the function
of components of the UPS have been associated with
many disease states, including oncogenesis [12], inflam-
mation [13,14], viral infection [15,16], CNS disorders
[17,18] and metabolic dysfunction [19]. The involvement
of a large number of components in the UPS suggests that
there may be many potential target sites for pharmacolog-
ical interference in the ubiquitin regulatory machinery
[20] (Figure 1). In this review, we assess advances in the
discovery and development of patented small-molecule
inhibitors of the major components of the UPS pathway
(see additional date file 1 for recent patent applications
related to inhibitors in the UPS), without considering pat-
ents on methods or target validation in the UPS.
Proteasome inhibitors
The attachment of ubiquitin to proteins to form K48-
linked polyubiquitin conjugates mostly results in proteo-
lytic degradation by a complex cellular structure, the pro-
teasome. Three proteasomal subunits (β 1, β2 and β5)
have enzymatic activities, described as chymotryptic-like,
tryptic-like and post-glutamyl peptidyl hydrolytic-like
[21]. Peptide boronic acids reversibly inhibit the chymot-
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ryptic-like activity of the proteasome very efficiently and
specifically. One compound, bortezomib (marketed
under the name of Velcade®[22]), was selected for inten-
sive studies and finally approved by the FDA in 2003 for
the treatment of multiple myeloma [10,23] and in 2006
for the treatment of mantle cell lymphoma (Figure 2a).
Closely related analogs of bortezomib, such as boronic
acid derivatives, benzylmalonic- and amino acid-based
derivatives, and boronic ester have been patented as pro-
teasome inhibitors [24,25]. Other compounds with
boronic acid or ester function, such as lactam derivatives,
have also been patented, with IC50 values in the low
nanomolar to 100 µM range, without results disclosed
[26].
In the wake of bortezomib and its analogs, a second gen-
eration of drugs targeting the proteasome is emerging.
These drugs include salinosporamide A (NPI-0052)
[27,28] (Figure 2b), a secondary metabolite derived from
a novel obligate marine actinomycete (Salinispora tropi-
cana), and its analogs [29]. NPI-0052 is a highly potent
and selective 20S proteasome inhibitor with irreversible
activity against all three catalytic sites. In preclinical stud-
ies, NPI-0052 has been shown to outperform bortezomib,
as it was active against myeloma cells resistant to borte-
zomib, steroids and thalidomide, and was less toxic to
normal cells. Studies using human multiple myeloma
xenografts showed that NPI-0052 is well tolerated, pro-
longs survival and reduces tumor recurrence, thus sup-
porting its use to treat multiple myeloma [30]. A phase I
trial was recently initiated in the US, in patients with solid
tumors and lymphomas. Open analogs of salinospo-
ramide A, such as 2-pyrrolidone derivatives from microor-
ganisms (Streptomyces JS360), have been also described
Schematic representation of the ubiquitin proteasome system Figure 1
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Representative proteasome inhibitors (a-n) Figure 2
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[31]. With a fluorogenic substrate, the most potent com-
pound (Figure 2c) was shown to inhibit human red blood
cell 20S proteasome activity in vitro with an IC50 of 0.2
nM. Other natural compounds, such as (–)-epigallocate-
chin 3-gallate ((–)-EGCG), the most abundant catechin in
green tea, act as chemoprotective and anticancer agents by
inhibiting the chymotrypsin-like activity of the purified
20S proteasome in vitro (IC50 of 0.086 µM; Figure 2d[32]).
Analogs of (–)-EGCG have been patented, the most
potent of which is a benzilate derivative with an IC50 of
0.59 µM against purified 20S proteasome [33,34] (Figure
2e).
A synthetic analog of epoxomicin, PR-171 [35], irreversi-
bly inhibits the chymotryptic site (Figures 2f-2g). Phase I
trials are underway, evaluating PR-171 in patients with
multiple myeloma and non-Hodgkin's lymphoma. Other
analogs of eponemycin and epoxomicin have been also
reported to inhibit the proteasome [36]. In this patent,
compounds such as ER-805751 (Figure 2h) were classi-
fied as bortezomib analogs with the boronic function
replaced by an epoxide group. This class of compounds
was tested in cell growth, cytotoxicity and proteasomal
activity assays, but no specific biological data were pre-
sented. However, xenograft studies with ER-805751 were
described. This compound inhibits MDA-MB-435 cell
growth when administered at doses of 5 and 10 mg/kg,
three days per week for four weeks.
Peptides with a sequence of up to 45 glutamine residues
linked to aldehyde, boronate or epoxyketone have been
shown to inhibit archaebacterial proteasomal activity in
vitro with minimal effects on mammalian proteasomes,
suggesting that they could be used to treat bacterial infec-
tions [37]. Lipopeptides and biotinylated-lipopeptides
have also been patented as non-covalently bound protea-
some inhibitors [38]. The most active of these compounds
are lipopeptides (Figures 2i-2j), which inhibit yeast 20S
proteasome activity in vitro with an IC50 of 35 µM. A fam-
ily of heteroaryl substituted tri- or tetra-peptide deriva-
tives has also been reported to inhibit proteasome activity
[39]. The inhibitory efficiency of various compounds,
such as that depicted in Figure 2k, was tested on human
26S proteasome activity in vitro, human tumor cell prolif-
eration and p21 accumulation in cells. This class of com-
pounds was described as active in these assays but no
specific biological data were disclosed. Tyropeptin A ana-
logs have additionally been patented as potent proteas-
ome inhibitors [40]. All the compounds presented in this
patent were aldehydes with the potential to act as irrevers-
ible analogs. The most potent compound (A7) (Figure 2l)
exhibited an IC50 of 18.5 nM in HCT-8 human colon car-
cinoma cells.
Finally, known proteasome inhibitors (bortezomib,
MG132 (Figure 2m) and ritonavir (Figure 2n)) have also
been patented for additional indications, such as neuro-
degeneration [41,42], contraception [43], cardiovascular
dysfunction [44], fibrosis [45], dry eye disorder [46] and
viral infections [47,48], indicating many potential thera-
peutic indications for proteasome inhibitors. A more
exhaustive description of the different classes of proteas-
ome inhibitors, not only restricted to patented inhibitors,
has been reviewed in detail elsewhere [10,49].
E1-conjugating enzyme inhibitors
A family of benzothiazole derivatives has been reported to
inhibit the E1 activating agent, preventing the transfer of
ATP-activated ubiquitin to different E2 conjugating agents
(UbcH10 and UbcH5c) in an in vitro fluorescent assay
[50]. These inhibitors, which compete for ATP, are illus-
trated in Figure 3a. Another patent claimed to have iden-
tified inhibitors of mouse ubiquitin-activating enzyme E1
(UBE1) by monitoring E2 (Ubc2)–ubiquitin complex for-
mation (IC50 below 100 nM) using homogeneous time-
resolved fluorescence (HTRF®) assays [51] (represented in
Figure 3b). Proliferation and in vivo anti-tumor efficacy
have been assessed for this class of compounds, but the
results have not been disclosed. The compounds included
in both patents require further investigation, focusing on
specificity and cell pharmacology, to confirm that E1
enzymes are relevant targets for the UPS. Indeed, it is
likely that multiple pathways could be affected by target-
ing the E1 machinery and we cannot exclude that many of
these pathways could be important for the functions of
normal cells.
E3 ubiquitin ligase inhibitors
E3 ubiquitin ligases form two major classes: (i) the HECT
(homologous to E6AP C-terminus) domain E3s, which
bind their cognate E2s and transiently accept ubiquitin at
a cysteine residue [52], and (ii) the RING (really interest-
ing new gene) domain E3s, which function as scaffold
proteins without forming a thiolester intermediate [53].
The RING domain E3s exist as a single peptide or as mul-
tiple-component complexes [54].
Small molecule inhibitors of E3 ligase-mediated p27
ubiquitylation have been patented [55]. However, despite
claims that these compounds could regulate ubiquityla-
tion, their in vitro activities and the drug target are not pre-
sented. Such compounds (compound 17 in additional
data file 1; Figure 4a) induce G1 arrest and apoptosis in
MDA-MB-435 human breast cancer cells. Several specific
E3 ubiquitin ligase inhibitors are discussed below.
TRAF6 inhibitors
The RING E3 ligase TRAF6 is involved in NF-κB signaling
[56]. Since the NF-κB pathway is involved in many impor-BMC Biochemistry 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2091/8/S1/S14
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tant processes such as inflammation and cell survival,
inhibition of the ubiquitin ligase activity of TRAF6 could
be relevant to the treatment of inflammation and cancers
[57]. Several benzoxadiazole derivatives were shown to
inhibit TRAF6 autoubiquitylation in vitro (IC50 below
1µM), in the presence of Uev1A and Ubc13, by ELISA and
western blot experiments [58]. These compounds were
also shown to affect proliferation of A549 and H1299 can-
cer cell lines using a cell viability assay (1≤IC50<20 µM;
Figure 4b).
POSH inhibitors
POSH is an E3 ubiquitin ligase containing a RING
domain. The ubiquitylation activity of human POSH is
required to target the HIV Gag protein to the plasma
membrane and is essential for HIV type-1 production
[59]. In vitro POSH autoubiquitylation assays identified
13 series of POSH antagonists [60]. Series 1, 3 and 4
appear the most promising, with IC50 values below 1 µM
(compounds 19, 20, 21 in additional data file 1; Figures
4c-4e). Interestingly, these compounds are more selective
for POSH activity than for the activities of the MDM2, c-
CBL and E2 enzymes, and they affect the maturation of
HIV particles in a virus-like particle assay (less than 50 %
at 3 µM).
Inhibitors of the MDM2/p53 axis
MDM2, a member of the RING E3 family, is a crucial reg-
ulator of p53 stability [61]. MDM2 is amplified or over-
produced in many malignant tumors [62], and p53
pathway activation by MDM2 inhibition is well estab-
lished as a target in the development of new therapeutic
agents for cancer [63]. A family of 5-deazaflavin deriva-
tives (including HLI98, Figure 4f) has been identified as
inhibiting MDM2 ubiquitin ligase activity [64,65]. These
compounds, which stabilize p53 and MDM2, and induce
apoptosis, establish proof-of-principle for the inhibition
of E3 ligase activity. However, the development of more
drug-like analogs is required for future clinical develop-
ment. Heterocyclic derivative inhibitors of MDM2-medi-
ated p53 ubiquitylation were recently described in
vitro[66]. These compounds (illustrated here by com-
pound 23 (see additional data file 1) (Figure 4g) and a
family including compounds 24a, b and c (see additional
data file 1) (Figures 4h-4k)) have been shown to decrease
cancer cell proliferation using a cell viability assay and to
increase p53-dependent transcription using stable cells
carrying a p53-dependent transcriptional regulatory ele-
ment linked to a luciferase reporter gene. However, the
effects of these compounds on autoubiquitylation of APC,
a cell cycle-regulated E3 ubiquitin ligase that controls
both entry and exit from mitosis, render the interpretation
more difficult [67]. Active rhodanine derivatives have also
been patented for inhibiting MDM2-mediated p53 ubiq-
uitylation, with an IC50 of 74 nM for the most potent com-
pound (Figure 4l) [68]. No cellular data were disclosed,
but specific compounds, such as compound 26 (Figure
4m), which inhibits MDM2-mediated p53 ubiquitylation
(0.45 µM) more efficiently than APC2/APC11 autoubiq-
uitylation (IC50>1000 µM), were identified.
Inhibitors of the MDM2–p53 interaction
MDM2-mediated p53 ubiquitylation can also be inhib-
ited by directly targeting the protein–protein interaction
between p53 and MDM2. Nutlins, which are derived from
cis-imidazoline (Figure 5a), and were recently identified
by high-throughput screening and structure-based opti-
mization, are the first potent and selective patented small
molecule inhibitors of the p53–MDM2 interaction
[69,70]. These compounds bind MDM2 and inhibit
growth of osteosarcoma and colon carcinoma cell lines in
a p53-dependent manner. They have also been shown to
suppress the growth of established osteosarcoma
xenografts in nude mice. Another compound, RITA, was
Representative E1 conjugating enzyme inhibitors (a-b) Figure 3
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identified in a cell proliferation assay with isogenic cancer
cells differing in p53 status (HCT116 colon cancer cells).
This compound has been shown to bind p53 in vitro using
fluorescence correlation spectroscopy and to prevent
p53–MDM2 interaction in vitro and in vivo, thus inducing
the accumulation of p53 in U2OS osteosarcoma cell lines
[71]. The same group (at the Karolinska Institute) also
identified, by ELISA experiments, tricyclic derivatives [72]
as inhibitors of the p53–MDM2 interaction and con-
firmed their inhibitory effects in HCT116 cells; namely
decreased p53 ubiquitylation and increased p53 levels
(Figure 5b). This compound was also shown to inhibit the
growth of HCT116 and U2OS cells in a p53-dependent
manner using cell viability and colony formation assays.
Design of compounds based on the structure of the
MDM2–p53 binding pocket led to the identification of an
entirely new class of MDM2–p53 antagonists based on
the spirooxindole core structure. Some of these inhibitors
specifically inhibit the growth of a p53-positive prostate
cancer cell line [73,74]. One such compound, Ke-43 (Fig-
ure 5c), inhibits the p53–MDM2 interaction competi-
tively, with an IC50 of 18 nM. Interestingly, a correlation
between in vitro and cellular activity has been demon-
strated. Other compounds, such as isoindolin-1-one-
based inhibitors or 1,4-benzodiazepinedine derivatives
(Figures 5d-5f), have been shown to inhibit p53–MDM2
Representative E3 ubiquitin ligase inhibitors (a-m) Figure 4
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interaction  in vitro (in the micromolar range) and to
induce p53-dependent gene transcription in cancer cell
lines [75-78].
Small molecules, such as substituted 4-Phenylpiperazine
[79], or substituted piperidine [80], were identified as
antagonists of the p53–MDM2 interaction in ELISA assays
in vitro, with activity in the micromolar range; however,
no cell pharmacology studies were carried out for these
molecules (Figures 5g-5h). Several compounds selected
for their ability to induce p53 and to decrease cell prolif-
eration in U87MG glioblastoma cells (IC50 approximately
10 nM) have recently been patented [81] (compound 35
in additional data file 1; Figure 5i). However, the mecha-
nism leading to p53 upregulation was not described.
These families of compounds differ structurally and are
leading candidates for the development of anti-cancer
drugs.
Deubiquitylating enzyme inhibitors
Another way to interfere with the UPS is to target the ubiq-
uitin deconjugation system, by inhibiting deubiquitylat-
ing enzymes. The human genome encodes approximately
95 putative DUBs [11], divided into five subclasses, of
which the USP (ubiquitin-specific protease) and UCH
(ubiquitin C-terminal hydrolase) enzymes are the best
characterized [11].
The first patented small molecule inhibitors of cellular
ubiquitin isopeptidases (cyclopentenone PNGs), which
Representative inhibitors of the p53–MDM2 interaction (a-i) Figure 5
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have been identified using ubiquitin–PEST and z-LRGG–
AMC as substrates, induce cellular accumulation of poly-
ubiquitylated proteins and cause apoptosis in colon can-
cer cells [82-84] (Figures 6a-6b). Interestingly, cell death
correlated with inhibition of isopeptidase activity. How-
ever, the existence of any selective inhibition on the vari-
ous isopeptidase family members has not been disclosed.
A molecular determinant conferring activity has been
identified in this class of inhibitors, leading to the charac-
terization of additional inhibitors with similar activities,
such as dibenzylideneacetone (DBA), curcumin and
shikoccin (NSC-302979) (Figures 6c-6e).
USP7 (or HAUSP) silencing results in p53 induction
mainly due to the deubiquitylating activity of USP7 on its
primary target, MDM2 [85,86]. In addition, USP7 has
been recently involved in deubiquitylation of monoubiq-
uitylated FOXO4, thus resulting in FOXO4 inactivation by
nuclear export and upregulation of the oncogenic PI3K/
PKB signaling pathway [87]. These findings suggest that
the targeting of USP7 with small molecule inhibitors
could be useful for treating cancer. High-resolution anal-
yses of the structures of USP7 in complex with some of its
substrates (MDM2, p53 and EBNA1) have identified a
consensus sequence for USP7 binding [88,89]. Recently
patented are synthetic inhibitors of USP7 protein binding
containing the polypeptide portion P1-Gly-P3-Ser, where
P1 is a glutamic acid residue or an amino acid with a non-
polar side chain and P3 is a glycine residue or an amino
acid with a non-polar side chain [90]. High-throughput
screening of 65,000 molecules for full-length USP7
cysteine protease activity in vitro led to the identification
of several drug-like hits [91]. One such molecule, HBX
41,108 (IC50 values of 0.53 µM), stabilizes p53 in vitro,
activates p53 target gene transcription without genotoxic
stress in HCT116 colon cancer cells, inhibits cell growth
and promotes apoptosis [92].
Ubiquitin-specific protease-8 (USP8) silencing has been
shown to induce G1 arrest and apoptosis in several tumor
cell lines. Small molecule inhibitors of USP8
(HBX 90,397 and HBX 90,659) have been shown to
inhibit HCT116 and PC3 cell growth, and to display spe-
cificity for USP8 among a panel of cysteine proteases [91].
Compounds active on USP2 and UCH-L3 have also been
identified in a fluorescence polarization assay [93]. The
compounds are disclosed to show IC50 values ranging
Representative deubiquitylating enzyme inhibitors (a-e) Figure 6
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from 100 nM to 50 µM for UCH-L3 and 100 nM to 100
µM for USP2. No specific biological data are presented.
Additional intervention points in the UPS
Inhibitors of the ubiquitylated substrate/proteasome 
interface
A chemical genetic screen of more than 100,000 com-
pounds in Xenopus extracts led to the identification of
ubistatins, which block the binding of ubiquitylated sub-
strates to the proteasome [94,95]. Compounds 41 and 42
(see additional data file 1) (Figures 7a-7b) compete with
the ubiquitin chain receptors of the proteasome for bind-
ing to the ubiquitin–ubiquitin interface of ubiquitylated
substrates. Despite their negative charges and lack of cell
permeability, ubistatins provide a new therapeutic inter-
vention point in the UPS.
Exogenous ubiquitin as an immunomodulator
Exogenous ubiquitin has been reported to have anti-
inflammatory effects in endotoxic and traumatic shock
[96,97], and this discovery has been patented [98]. This
immunomodulatory property could be used for new
approaches to the treatment of inflammation. Little is
known about the mechanism of action of exogenous
ubiquitin, but its uptake and conjugation to intracellular
proteins have recently been demonstrated, providing a
new method of interfering with the UPS after inflamma-
tory stimuli [99].
Conclusion and new frontiers
The increasing number of patented inhibitors affecting
the UPS discovered over the last three years clearly illus-
trates a growing interest in this system as a target pathway
for the development of new therapies. New proteasome
inhibitors now in clinical development, such as NPI-0052
or PR-171, appear to be promising candidates to follow
on from bortezomib in cancer treatment. The ‘passive’
role traditionally attributed to the proteasome is being
challenged by the discovery of proteasome-associated
proteins involved in the modulation of proteasome func-
tion, such as ubiquitin binding proteins, E3 ubiquitin
ligases or deubiquitylating enzymes. In that context, we
can hypothesize that targeting these proteins rather than
targeting the classical proteasomal catalytic sites may
result in distinct phenotypes.
Upstream from the proteasome, the UPS provides many
additional targets for small molecule inhibitors (Figure
1). These potential therapeutic intervention points, such
as E3 ligases or deubiquitylating enzymes, are now tar-
geted for inhibition by small molecules. The main strate-
gies consist of either selectively blocking the catalytic
activity of these enzymes or preventing the enzyme–sub-
strate interaction. Due to the important role of MDM2 in
promoting degradation of the p53 tumor suppressor, con-
siderable efforts have been devoted to the identification of
MDM2 inhibitors. Some of these compounds, such as
Nutlins, appear very promising as cancer therapeutics
since they are effective in animal models upon oral
administration without noticeable toxicity. These inhibi-
tors of the p53–MDM2 interaction also provide strong
support for the therapeutic application of selective disrup-
tion of protein–protein interactions. Inhibition of E3
ligase activity is still a significant challenge due to the
complexity of the ubiquitin conjugation system. Indeed,
even with the less complex (HECT) monomeric E3 ligases
(when compared with the multi-components E3s), bio-
chemical assay requires at least two additional enzymes:
an E1 and an E2. In this context, counterscreens must be
performed to eliminate non-selective hits and thiol-reac-
tive compounds.
Representative inhibitors of the ubiquitylated substrate/proteasome interface (a-b) Figure 7BMC Biochemistry 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2091/8/S1/S14
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Regarding most of the deubiquitylating enzymes, there is
no need to supply additional purified proteins for HTS
(high-throughput screening) assays. These proteins also
appear more “drugable” than E3 ubiquitin ligases since
many of them belong to the large cysteine protease family,
a family of enzymes presently targeted by more than ten
cysteine protease inhibitors at various phases of clinical
development/trials for diverse diseases [100,101]. Future
studies, particularly aimed at identifying potential sub-
strates of deubiquitylating enzymes, as well as at deter-
mining the effects of loss of function of these enzymes,
will rapidly advance our understanding of the roles of
DUBs. Current efforts on this class of enzymes are also
focusing on development of biochemical HTS assays
based on cleavage of specific ubiquitylated substrates.
Since proteasome activity is essential for the survival of
any cell, proteasome inhibition targets an essential func-
tion. As such, bortezomib represents a novel generation of
cytotoxics. Unfortunately, it suffers, like most of the other
chemotherapeutics, from a narrow therapeutic index.
Compounds targeting oncogenic E3 ligases or DUBs
could show a better specificity, a lower toxicity and possi-
bly a better potency than proteasome inhibitors.
The current focus for UPS-targeted therapies is cancer, but
given the dysregulation of the UPS in many other diseases
such as inflammation, metabolic dysfunction, CNS disor-
ders and infectious diseases, it is not unreasonable to
expect more drug discovery efforts related to these pathol-
ogies in the near future.
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